

## Declaration of Interests Register

**Technology Appraisal Committee A**

**Publication Date: 15/01/2020**

**Topic: TA619 Palbociclib with fulvestrant for treating advanced, hormone-receptor positive, HER2-negative breast cancer after endocrine therapy [ID916]**

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Jeremy Braybrooke	Committee member	Direct non-financial professional interest	Has been co-investigator on clinical trials with CDK 4/6 inhibitors in breast cancer, including palbociclib and ribociclib. These trials are now closed to recruitment.		October 2019		Declare and participate.
Mark Upton	Committee member	Expired	Was employed by Pfizer for 9 weeks in 1999. Holds no stocks or shares in Pfizer.		October 2019	1999	Participate.
Anne Rigg	Expert adviser	Direct financial	Received honoraria for advisory board and speaking work from Genomic Health, Roche, Novartis, Pfizer and Amgen. Chair of chemotherapy clinical reference group (CRG) for NHS England.	Over last 5 years	October 2019		Declare and participate. Not involved in decision making.

Holly Heath	Expert adviser	Indirect	Her employer, Breast Cancer Now, received £2.7m of income from Pfizer for their Catalyst programme, which provides grants for research. The work on access to drugs is independent of any funding received from pharmaceutical companies and is based on the evidence of the clinical effectiveness of drugs.	2016/17	October 2019		Declare and participate. Not involved in decision making.
-------------	----------------	----------	---	---------	--------------	--	---

Link to Committee A interests register : <https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-committee/TAC-A-interests-register.pdf>

#### GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.